在患有质瘤的儿童中准RAS/MAPK通路
Chantel Cacciotti1,2, Uri Tabori3,4, Cynthia Hawkins4,5
1Division of Pediatric Hematology/Oncology, London Health Sciences Centre, London, ONT, Canada. chantel.cacciotti@lhsc.on.ca.
针对儿科质瘤的向治疗,特别是低度质瘤 (pLGG),已经显示出优异的结果. RAS/MAPK路径的改变驱动了这些瘤,导致了精准医学方法,但对于高度质瘤 (pHGG) 仍然存在疑问.
科学领域:
- 在瘤学瘤学.
- 儿科神经瘤学 儿科神经瘤学
- 分子向疗法分子向疗法
背景情况:
- 儿科质瘤,包括儿科低度质瘤 (pLGG) 和儿科高度质瘤 (pHGG),是儿童中最常见的脑瘤.
- 在大多数pLGG和部分pHGG病例中,RAS/MAPK路径的改变是主要的驱动因素.
- 这些分子变化的鉴定为有针对性的治疗干预铺平了道路.
研究的目的:
- 审查RAS/MAPK途径向治疗在治疗儿科质瘤中的当前作用.
- 讨论围绕这些向治疗的现有争议和未解决的问题.
主要方法:
- 对针对性治疗治疗的儿科质瘤临床试验数据和治疗结果的审查.
- 分析RAS/MAPK路径改变对治疗疗效的影响.
- 检查儿童质瘤向治疗的挑战和未来方向.
主要成果:
- 与pLGG的传统化疗相比,向疗法已经显示出优异的结果,这导致其在某些场景中被用于前线治疗.
- 在过去的十年里,有针对性的治疗改变了儿科低度质瘤患者的护理环境.
- 挑战仍然存在,包括最佳治疗持续时间,独特的毒性概况,以及对pLGG疾病自然史的长期影响,以及针对性治疗在pHGG的组合治疗和耐药性机制中的作用.
结论:
- 针对RAS/MAPK的向疗法代表了显著的进步,使儿童质瘤能够转向精准医学.
- 需要进一步的研究来解决PHGG向治疗的复杂性,并优化其在所有儿科质瘤亚型中的应用.
- 对争议和悬而未决的问题进行持续调查对于完善治疗策略至关重要.
更多相关视频
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
相关概念视频
MAPK Signaling Cascades
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
